Clear All
11888 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68382-0914-06 68382-0914 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 30, 2020 In Use
62332-0566-30 62332-0566 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jul 9, 2021 In Use
46708-0567-30 46708-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jul 9, 2021 In Use
72205-0082-30 72205-0082 Erlotinib Hydrochloride Erlotinib Hydrochloride 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
62332-0567-90 62332-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jul 9, 2021 In Use
63304-0135-30 63304-0135 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 5, 2019 In Use
72485-0217-30 72485-0217 Erlotinib hydrochloride Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 6, 2019 In Use
55513-0956-21 55513-0956 Panitumumab Vectibix 400.0 mg/20mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 1, 2025 In Use
67184-0531-01 67184-0531 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb 13, 2023 In Use
68382-0915-16 68382-0915 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 30, 2020 In Use
59651-0530-10 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jun 22, 2022 In Use
00002-7716-01 00002-7716 Necitumumab Portrazza 16.0 mg/mL Immunotherapy Monoclonal Antibody EGFR Intravenous Nov 24, 2015 In Use
68382-0913-06 68382-0913 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 30, 2020 In Use
67184-0531-02 67184-0531 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb 13, 2023 In Use
55513-0956-01 55513-0956 Panitumumab Vectibix 400.0 mg/20mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 10, 2006 In Use
00069-0197-30 00069-0197 dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 In Use
69339-0168-03 69339-0168 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jun 5, 2023 In Use
59651-0532-03 59651-0532 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jun 22, 2022 In Use
46708-0567-90 46708-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jul 9, 2021 In Use
55513-0954-21 55513-0954 Panitumumab Vectibix 100.0 mg/5mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 1, 2025 In Use
69539-0091-30 69539-0091 Erlotinib Hydrochloride Erlotinib Hydrochloride 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
59651-0531-10 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jun 22, 2022 In Use
55513-0954-01 55513-0954 Panitumumab Vectibix 100.0 mg/5mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 10, 2006 In Use
63020-0040-90 63020-0040 Mobocertinib EXKIVITY 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Sep 15, 2021 Mar 31, 2025 No Longer Used
66733-0958-23 66733-0958 Cetuximab Erbitux 2.0 mg/mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 2, 2007 In Use

Found 11888 results — Export these results